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Abstract: WWP2 is an E3 ubiquitin ligase that differentially regulates the contextual tumour
suppressor/progressor TGFβ signalling pathway by alternate isoform expression. WWP2 isoforms
select signal transducer Smad2/3 or inhibitor Smad7 substrates for degradation through different
compositions of protein–protein interaction WW domains. The WW4 domain-containing WWP2-C
induces Smad7 turnover in vivo and positively regulates the metastatic epithelial–mesenchymal
transition programme. This activity and the overexpression of these isoforms in human cancers make
them candidates for therapeutic intervention. Here, we use NMR spectroscopy to solve the solution
structure of the WWP2 WW4 domain and observe the binding characteristics of Smad7 substrate
peptide. We also reveal that WW4 has an enhanced affinity for a Smad7 peptide phosphorylated at
serine 206 adjacent to the PPxY motif. Using the same approach, we show that the WW3 domain
also binds Smad7 and has significantly enhanced Smad7 binding affinity when expressed in tandem
with the WW4 domain. Furthermore, and relevant to these biophysical findings, we present evidence
for a novel WWP2 isoform (WWP2C-∆HECT) comprising WW3–WW4 tandem domains and a
truncated HECT domain that can inhibit TGFβ signalling pathway activity, providing a further
layer of complexity and feedback to the WWP2 regulatory apparatus. Collectively, our data reveal
a structural platform for Smad substrate selection by WWP2 isoform WW domains that may be
significant in the context of WWP2 isoform switching linked to tumorigenesis.
Keywords: TGFβ signalling; transforming growth factor beta; smad; smad7; E3 ubiquitin ligase;
NEDD4; WW domain; protein interaction
1. Introduction
Polyubiquitination, a process in which E3 ligase activity earmarks substrates for degradation at
the proteasome by the attachment of ubiquitin chains, is an essential step in protein regulation [1,2].
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This targeted degradation is part of the ubiquitin/proteasome system (UPS) which controls protein
levels across a wide variety of physiological pathways. Dysfunction of this process is implicated in
the pathogenesis of a range of diseases, including cancers, neurodegenerative diseases, inflammatory
disorders and many others [3]. Accordingly, components of the UPS are the targets of several approved
drugs and candidate targets for novel therapeutic intervention [4,5]. The protein–protein interaction
domains of E3 ligases are particularly appealing targets, since they confer specificity to the ubiquitin
pathway through selective binding of target substrates and they offer the lowest likelihood of off-target
effects. Targeting protein–protein interaction domains has historically been considered challenging,
but new approaches have facilitated the design of several successful protein–protein interaction domain
inhibitors [6–8], including for an E3 ligase [9].
WWP2 belongs to a subset of nine closely related HECT E3 ligases referred to as the NEDD4
family. Their defining characteristic is the presence of modular protein–protein interaction structural
motifs called WW domains which are used to recruit substrates with short proline-rich motifs [10].
Despite these short binding motifs and their simple three-stranded antiparallel β-sheet secondary
structure, WW domains confer specificity to the NEDD4 E3 ligases by differentiating between a broad
range of target substrates [11]. These substrates are often linked to oncogenic pathways such as
the tumour suppressor PTEN, the oncogene OCT4 (octamer-binding transcription factor 4), genome
stability components, the Wnt pathway, the EGFR (epidermal growth factor receptor) pathway and the
TGFβ (transforming growth factor-β) pathway [12]. These signalling pathways are often disrupted in
human malignancies, and several NEDD4 family members, including NEDD4, NEDD4L, SMURF1,
SMURF2, WWP1 and WWP2, also have altered expression or splicing in cancer [13].
This has led to a significant effort to characterise the regulatory role of NEDD4 family members.
In particular, interactions with components of the TGFβ signalling pathway have been intensively
studied. These components include Smad2 and Smad3, which are phosphorylated by serine/threonine
kinase receptors at the cell surface and translocate to the nucleus. Here they recruit cofactors at
genetic elements to induce transcriptional activation or suppression of a large number of unrelated
and often contradictory genes, including Smad7, which inhibits the pathway to create a negative
feedback loop. The genes regulated by TGFβ are central to cytostasis, proliferation, apoptosis,
cell survival, cell adhesion and migration, stem cell pluripotency, differentiation and extracellular
matrix reorganisation. As a result, this pathway plays an important role in development [14],
immunity [15] and tissue homeostasis and repair [16,17]. The powerful gene programmes are
harnessed in cancers [18] and misregulated in connective tissue, skeletal, inflammatory and immune
diseases [19–21]. The defining characteristic of TGFβ signalling is its ability to sense the local
environment and elicit diverse signalling outcomes based on the cellular context [22]. This is achieved
by an exquisite regulation of each step in the pathway by an array of independently regulated
binding partners, creating a complex biological algorithm. UPS input into this algorithm involves
the interplay between ubiquitin ligases and deubiquitinating enzymes such as the ubiquitin-specific
proteinases [23,24]. The NEDD4 family of E3 ubiquitin ligases have been found to interact with and
cause the degradation of both the activating components (Smad2, Smad3 and TGFβ receptor-I) and
the inhibitory component (Smad7). These E3 ligases create their own complex web of regulation that
includes differential isoform-splicing and phospho-regulation [25–27] and, in so doing, they integrate
the UPS, kinase pathway crosstalk and splicing programmes into the regulation of TGFβ signalling.
The nature of the interaction between WW domain and Smad substrate is critical to this regulatory
activity and in defining a niche for each ligase. NEDD4L, for example, binds to the PPxY motifs in
the linker region of TGFβ-activated Smad2 and Smad3 exclusively through its second WW domain,
but only once they have been phosphorylated by CDK8/9 [25]. This phosphorylation occurs two
residues N-terminal to the PPxY motif and directly affects the interaction between the NEDD4L
WW2 domain and Smad2/3, enhancing their turnover through proteasome-mediated degradation [26].
On the other hand, SMURF1 binds Smad7 with high affinity, translocates to the cytoplasm and is
recruited to TGFβ receptor I (TβR-I) via Smad7 interaction with the receptor. Here, TβR-I and Smad7
Int. J. Mol. Sci. 2019, 20, 4682 3 of 20
are polyubiquitinated, causing their degradation at the proteasome [28,29]. The SMURF1/Smad7
interaction is mediated by a synergistic action between SMURF1 tandem WW domains, a mechanism
that is found amongst other tandem WW domain-containing proteins [30] and is also evident in its
homolog SMURF2 [31,32]. This allows the interaction to be tuned by alternative transcript splicing,
and the incorporation of a stretch of amino acids between these tandem domains diminishes the
coordinated high-affinity binding of Smad7 [31].
Isoform-mediated regulation of the TGFβ signalling pathway is not a feature unique to SMURF1.
WWP2 is found to be expressed as three distinct isoforms that arise from alternative splicing and
alternative promoter activity, with the capacity to either positively or negatively regulate TGFβ
signalling [27]. This ability to regulate both the signal transducers (Smad2/3) and the negative feedback
loop (Smad7) in a discrete manner is interesting, given the highly contextual nature of TGFβ signalling
outcomes [33]. The divergent activity of WWP2 isoforms is apparently allowed by the incorporation
of different WW domains with different substrate preferences within their sequence. WWP2-FL
contains the full complement of WW domains and is observed to bind Smad2/3 and Smad7 in vivo,
the N-terminal isoform WWP2-N has preference for Smad2/3 but also plays a role in relinquishing
WWP2 autoinhibition, while the C-terminal isoform WWP2-C has preference for Smad7 [34]. Indeed,
this substrate selectivity has been shown to play a direct role in the pathology of cardiac fibrosis through
the regulation of Smad2 by WWP2-N [35], while the overexpression of WWP2 isoforms in early and
advanced disease stages in cancer cDNA panel arrays indicates their potential as targets for therapeutic
intervention [36]. As a negative regulator of Smad7, WWP2-C propagates downstream TGFβ signalling
gene programmes, including that of epithelial–mesenchymal transition (EMT). The critical role this
process plays in the invasion and migration of tumours during metastasis makes this isoform of great
interest in drug development.
High-resolution protein structures and binding site elucidation are required to inform rational
drug design [7]. Some effort has been made to elucidate the structure of WWP2, with success in
the crystallisation of the HECT domain [37] and a WW2-HECT construct [38], but with difficulty
encountered in the expression and purification of individual WW domains [39]. We also found
WWP2 and its domains difficult to express and purify, but here we have succeeded in improving the
purification yield of WWP2 WW domains. We used our approach to solve the structure of the WW4
domain by nuclear magnetic resonance (NMR) spectroscopy. By measuring chemical shift changes
by NMR, we observed the in vitro interaction between WW4 and Smad7 and uncovered a potential
role for phospho-regulation of WWP2-mediated Smad7 degradation. We present evidence for a novel
WWP2 isoform called WWP2C-∆HECT which utilises a tandem WW3–WW4 domain pair to regulate
the TGFβ pathway. We explored the role these tandem domains play in substrate recruitment by
using NMR to probe their Smad7 binding affinities. We found that the affinity of WW3 for Smad7 is
significantly enhanced in the presence of its tandem WW4 domain. These findings have implications
in the context of substrate competition between WWP2 isoforms and add new insights into the WWP2
isoform-mediated negative feedback loop of the TGFβ pathway.
2. Results
2.1. WWP2 WW4 Adopts The Canonical WW Domain Fold
To solve the purification problems frequently encountered when attempting to purify WWP2 WW
domains, we expressed WW4 with an N-terminal small solubility-enhancing B1 domain of streptococcal
protein G (GB1) tag (Figure 1A). This produced a significantly enhanced yield and stability during
purification. Attempts at cleaving WW4 from its solubility tag resulted in comprehensive precipitation.
Since interaction between the two conjugated domains could disrupt the native conformation of WW4,
T1, T2 and heteronuclear Nuclear Overhauser effect (NOE) relaxation experiments were performed to
confirm that each domain behaves independently (Figure S1A–C), from which it was deemed acceptable
to proceed with the tag intact. A series of NMR spectroscopy experiments were used to assign 89% of
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atoms (available in the Biological Magnetic Resonance Data Bank (BMRB) [40] under accession code
34407). The unassigned atoms corresponded to three residues at the N-terminus, one serine within
loop 1 of WW4, five prolines (for which there are no observable amide resonances), and some sidechain
atoms throughout the sequence. A 20-model water-refined ensemble was produced from structural
calculations (available in the Protein Data Bank (PDB) under accession code 6RSS). No inter-domain
NOEs were observed between residues of the GB1 and WW4 domains, further indicating that the
presence of the tag did not interfere with the WW domain fold. As a result, the linker between the
two domains showed a high level of flexibility, giving a high backbone root-mean-square deviation
(RMSD) value (8.9 Å) and rendering global structure validation unsuitable. Instead, validation was
performed on the GB1 and WW4 domains separately, a summary of which is shown in Table 1. The GB1
domain holds the expected fold published elsewhere [41–43] (Figure S2A). WW4 holds the typical
three-stranded antiparallel β-sheet with a right-handed twist seen in other WW domains (Figure 1B
and Figure S2B). The fold is initiated by a type II β-turn between the linker and the first β-strand.
The first and second β-strands are connected by a β-turn (Loop 1) which is stabilised by hydrogen
bonding between the sidechain of 455Thr and the amide groups 457Glu and 458Val. The second and
third β-strands are linked by a five-residue loop (Loop 2), where the carboxyl group of residue 464Asp
forms hydrogen bonds with the amide groups of 467Thr, 468Arg and 469Thr. The third β-strand
extends four residues until 472Phe, which substitutes the typically conserved C-terminal tryptophan
found in other WW domains.
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Table 1. Summary of the NMR data and structure validation statistics for each domain.





Sequential (|i-j| = 1) 400
Medium-range (|i-j| < 4) 118
Long-range (|i-j| > 5) 412
Total dihedral angle restraints
ϕ 96
ψ 96
Structure statistics GB1 WW4
Violations (mean and s.d.)
Distance constraints (±0.3Å tolerance) 2 0
Dihedral angle constraints (±5◦ tolerance) 2 1
Max. dihedral angle violation (◦) 1.75 2.24
Max. distance constraint violation (Å) 0.043 -
Deviations from idealised geometry
Bond lengths (Å) 0.008 0.009
Bond angles (◦) 0.9 0.8
Impropers (◦) - -
Average pairwise RMSD 1 (20 refined structures) (Å)
Heavy 0.8 0.9
Backbone 0.4 0.4
1 Root-mean-square deviation (RMSD) for well-defined regions (GB1 residues 3–59, WW4 residues 75–101). Nuclear
Overhauser effect (NOE).
2.2. WWP2 WW4 Binds to A Smad7 and Phospho-Smad7 PPxY Motif
In previous experiments, we found that WWP2-mediated Smad7 degradation was significantly
enhanced on stimulation with TGFβ [27]. One possible explanation for this is enhanced substrate/ligase
affinity by post-translational modification of Smad7. Submission of the Smad7 amino acid sequence
to the phosphorylation-site prediction servers NetPhos 3.1 [44,45] and GPS 3.0 [46] identified S206 in
close proximity to the PPxY motif as a potential phosphorylation site (Figure 2A, Tables S1 and S2).
We searched the literature for experimental evidence of S206 phosphorylation and found that in vivo
expression of the C-terminal portion of Smad7 resulted in phosphorylation at S206 [47]. Since WW4
domain-containing WWP2-C has preference for Smad7 interaction and degradation [27], and because
this domain shares a reasonable level of sequence similarity with Smad7-binding domains of the
SMURF homologs (Table S3), we used WW4 as a binding partner in titration experiments for short
Smad7 and S206-phosphorylated Smad7 (pSmad7) ligands. Using NMR spectroscopy to detect the
local molecular environment perturbation, we observed peak migration in a series of heteronuclear
single quantum coherence experiments (HSQCs) in which the ligand concentration was increased
(Figure 2B and Figure S3A, and Figure 2C and Figure S3B). This process is indicative of a fast-exchange
binding event between WW4 and Smad7/pSmad7 and confirms in vivo observations of interactions
between the WWP2 WW4 domain and Smad7. Dissociation constants (KD) were calculated from the
binding curve. This revealed a 2.3x increase in the affinity of WW4 for pSmad7 (0.5 ± 0.07 mM) when
compared to unphosphorylated Smad7 (1.19 ± 0.21 mM) (Figure 2D).
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Since changes in peak shift are caused by local electromagnetic field perturbation upon interaction
with the ligand, plotting the peak shift distances of each titration allowed us to identify the binding
site (Figure 2E,F). This provided insight into how WWP2-C binds to Smad7 in vivo and identified two
binding hotspot residues, 470Thr and 471Thr (in red). The pattern of binding across the WW4 domain
was almost identical for both phosphorylated and unphosphorylated Smad7. There were differences
in shift distance when comparing the same residues across the binding site, but no obvious variations
that might indicate direct polar contacts with the phosphate group, as seen in other examples [26].
All three β-strands exhibited electromagnetic field perturbation on ligand binding, with the third
β-strand exhibiting the most significant changes. Previous studies on WW domain/ligand co-structures
and binding assays identified two characteristic binding pockets on the WW domain surface that
determine specificity for the PPxY recognition motif. These are the XP-binding groove, which binds the
proline-rich N-terminal region [48], and a second specificity pocket that accommodates the tyrosine [49].
In WW4, the XP-binding groove is formed by 461Tyr and 472Phe, while the second specificity pocket is
formed by 463Val, 465His and 468Arg. Both pockets can be seen in the structure and both are involved
in binding (Figure 2F).
2.3. Evidence for A Novel WWP2 Isoform Which Contains Tandem WW3–WW4 Domains and A Truncated
HECT Domain That Can Inhibit TGFβ-Dependent Signalling Activity
In various western blots using an antibody specific for an epitope in the C-terminal region of
WWP2, we noticed cross-reactivity with a small protein band at approximately 33 kDa (Figure 3A).
Similar to other WWP2 isoforms, expression of this protein was inducible by TGFβ, and we were able
to suppress its expression in epithelial cells by transfection of various epithelial splicing regulatory
proteins (ESRPs) that are known to regulate specific gene splice events during the TGFβ-induced
epithelial cell differention programme [50]. Since no other protein-coding transcript registered in the
Genbank database could produce a protein product that was both the correct size and cross-reactive
with the anti-WWP2C antibody, we suspected that this band belonged to a novel WWP2 isoform
not yet reported in the literature. Searching the expressed sequence tag (EST) database produced
two hits within intronic regions of the wwp2 gene (Figure 3B). There is a TATA box within intron
9/10, 5′ of the DC341937.1 EST, indicating promoter activity that may control the expression of a
novel isoform. This intron contains a cluster of growth factor-responsive elements (Figure S4A),
and we observed a transcriptional response to TGFβ and EGF stimulation in luciferase reporter assays
(Figure S4B,C ). We found evidence of wwp2 transcript splice variation corresponding to both EST
DC341937.1 (Figure 3C) and EST BX471495.1 (Figure 3D) in metastatic cell lines. The theoretical
product of a transcript with both ESTs is a WWP2C-∆HECT isoform of approximately 38 kDa that
includes tandem WW3 and WW4 domains and a potentially catalytically inactive HECT domain
(Figure 3E). We created a construct that corresponds to this novel isoform and co-transfected HEK293A
cells with the Smad3-dependent CAGA12-luciferase reporter to test the effect of WWP2C-∆HECT
overexpression on TGFβ pathway transcriptional activity. We observed significant inhibition of
Smad-dependent promoter activity in cells stimulated with TGFβ (Figure 3F). This suggests that,
unlike WWP2-C which potentiates TGFβ signalling [27], the tentative WWP2C-∆HECT isoform could
suppress TGFβ/Smad-dependent signalling.
Int. J. Mol. Sci. 2019, 20, 4682 8 of 20
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 8 of 20 
 
 
Figure 3. Splice variation at the wwp2 gene. (A) A Western blot of HEK293A cells transfected with 
combinations of mouse and/or human epithelial splicing regulatory proteins (ESRPs) as indicated and 
stimulated with TGFβ; the membrane was probed with anti-WWP2C antibody or anti-β-actin 
antibody as a control. (B) The wwp2 gene locus (not to scale) with aligned transcripts and expressed 
sequence tag (ESTs) as annotated. (C) Semi-quantitative RT-PCR using primers targeting intron 9/10 
of wwp2 mRNA extracted from A375 cells treated with TGFβ over 18 hours. (D) Semi-quantitative 
RT-PCR using primers targeting exon 17–intron 19/20 of wwp2 mRNA extracted from COLO-357 and 
VCaP cells treated with TGFβ over 8 hours and from A375 and SK-MEL28 cells treated over 6 hours. 
(E) A schematic showing the domain composition of WWP2-FL, WWP2-C and the putative new 
isoform WWP2C-ΔHECT. (F) Fold change in luciferase activity in HEK293A cells co-transfected with 
WWP2C-ΔHECT and the Smad3-dependent CAGA12-luciferase reporter, treated and untreated with 
TGFβ, with standard error bars. 
2.4. WWP2 WW Domain Affinity for Smad7 Is Switched On when Expressed in Tandem 
The last tryptophan of WWP2 WW3 and the first tryptophan of WWP2 WW4 are separated by 
only 17 amino acids, and their role as tandem domains in both WWP2-FL and the tentative novel 
WWP2C-ΔHECT is undefined. WW domains are commonly found in other proteins as pairs, linked 
by a short stretch of amino acids, and are found to participate in cooperative or destructive binding 
in order to modulate substrate affinity. Since WWP2C-ΔHECT appears to inhibit TGFβ signalling 
despite lacking the cysteine required to catalyse the transfer of ubiquitin, we suspected that it may 
be interacting with the inhibitory Smad7 in an as yet undefined regulatory mechanism involving its 
tandem WW domains. To explore the role this tandem conformation plays in substrate recruitment, 
we used NMR titrations to probe the Smad7 affinity of tandem WW3–4, using a short PPxY Smad7 
ligand recombinantly expressed in Escherichia coli. Due to purification requirements, this peptide is 
four additional amino acids longer at the N-terminus than the synthetic peptide previously used. We 
observed evidence of ligand binding in the WW3–4 Smad7 titration HSQCs (Figures 4A and S5A). 
Closer inspection of the binding pattern revealed that peaks belonging to WW4 exhibited fast-
exchange migration, and so too did peaks belonging to the WW3 domain, some of which also 
Figure 3. Splice variation at the w . ( ) estern blot of HEK293A cells transfected with
combinations of mouse and/or hu an e it elial s lici g regulatory proteins (ESRPs) as indicated and
stimulated with TGFβ; the membrane was probed with anti-WWP2C antibody or anti-β-actin antibody
as a control. (B) The wwp2 gene locus (not to scale) with aligned transcripts and expressed sequence tag
(ESTs) as annotated. (C) Semi-quantitative RT-PCR using primers targeting intron 9/10 of wwp2 mRNA
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2.4. WWP2 WW Domain Affinity for Smad7 Is Switched On when Expressed in Tandem
The last tryptophan of WWP2 WW3 and the first tryptophan of WWP2 WW4 are separated by
only 17 amino acids, and their role as tandem domains in both WWP2-FL and the tentative novel
WWP2C-∆HECT is undefined. WW domains are commonly found in other proteins as pairs, linked
by a short stretch of amino acids, and are found to participate in cooperative or destructive binding
in order to modulate substrate affinity. Since WWP2C-∆HECT appears to inhibit TGFβ signalling
despite lacking the cysteine required to catalyse the transfer of ubiquitin, we suspected that it may
be interacting with the inhibitory Smad7 in an as yet undefined regulatory mechanism involving its
tandem WW domains. To explore the role this tandem conformation plays in substrate recruitment,
we used NMR titrations to probe the S ad7 affinity of tandem WW3–4, using a short PPxY Smad7
ligand recombinantly expressed in Escherichia coli. ue to purification requirements, this peptide is
four ad itional amino i longer at the N-terminus than the synthetic p ptide previously used.
We observed evidence of ligand binding in the WW3–4 Smad7 titration HSQCs (Figure 4A and
Figure S5A). Closer inspectio of the binding pattern reveal d that peaks bel nging to WW4 exhibited
fast-exchange migration, and s too did peaks belo ing o the W3 domain, some of w ich also
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exhibited intermediate exchange peak broadening. When we performed the same titrations on WW3
and WW4 as individual domains, we found that WW3 (Figure 4B and Figure S5B), as well as WW4
(Figure 4C and Figure S5C), bound Smad7 independently. For these single domain titrations, binding
did not reach saturation, but curve fits to fast-exchange peak migration patterns were good, and
errors were small enough to determine the dissociation constants. This revealed a greater affinity for
WW3/Smad7 (139 ± 14.4 µM) compared to WW4/Smad7 (237 ± 15.7 µM). The observed affinity of WW4
for Smad7 was much higher for the expressed ligand compared to our synthetic peptide titrations
in Figure 2B (1.19 ± 0.21 mM). This may be a result of the longer ligand holding a more favourable
binding conformation or it could be due to synthetic peptide contaminants that disrupted binding,
and indeed we found non-specific peak migration across GB1 and WW4 domains at high synthetic
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Figure 4. The interaction between tandem WP2 WW3–4 and Smad7. (A) The superimposed
WW3–4/Smad7 titration HSQCs. Lower ligand concentrations are in light orange, and higher ligand
concentrations are in dark orange. (B) The superimposed WW3/Smad7 titration HSQCs. Lower
ligand concentrations are in light green, and higher ligand concentrations are in dark green. (C) The
superimposed WW4/Smad7 titration HSQCs. Lower ligand concentrations are in light purple, and
higher ligand concentrations are in dark purple. (D) The shift distances of the WW3–4/Smad7 (orange),
WW3/Smad7 (green) and WW4/Smad7 (purple) titration HSQC amide peaks in ppm. The WW3–4
seconda y structure is aligned to the residue number along the x-axis, with β-strands represented as
yellow boxes (E) The W3–4/S ad7 binding curve KD fit. (F) The WW3/Smad7 (139 ± 14.4 µM),
WW3(tandem)/S ad7 (20.57 ± 26.24 µM), WW4/Smad7 (237 ± 15.7 µM) and WW4(tandem)/Smad7
(249.3 ± 68.1 µM) dissociation constants. (G) HSQC peaks belonging to the WW3 domain at different
chemical shifts for WW3–4 (orange) and WW3 (green).
Int. J. Mol. Sci. 2019, 20, 4682 10 of 20
Since the pattern of binding was similar for the respective domains in the single and tandem domain
titrations (Figure 4D), it was assumed that WW3–4 binds the Smad7 ligand in a 2:1 ligand–receptor
stoichiometry, with each WW domain binding site accepting one ligand. For the tandem domain data,
the dissociation constants were calculated by fitting a curve to the combined binding data using a
two-site binding equation (Figure 4E). Although this produced dissociation constants with higher
standard deviations (Figure 4F), we were able to discern certain characteristics. Significantly, when
both domains were expressed in tandem, WW3 domain affinity increased approximately seven-fold
to 20.57 ± 26.24 µM, while WW4 affinity remained approximately the same at 249.3 ± 68.1 µM.
These results are consistent with the raw data, which show WW3 residues reached close to saturation
at lower ligand concentrations compared to WW4. The tandem WW4 domain peaks exhibited an
identical, albeit consistently smaller, pattern of peak shift change as those of the single domain
(Figure 4D), and the WW4 peaks of the free HSQC spectra for both constructs had identical chemical
shifts. These observations strongly suggest that WW4 holds the same conformation and has the same
binding mechanism in both single and tandem proteins, while the consistently smaller change in peak
shift across the tandem WW4 binding site is expected of a domain in competition with its neighbour.
The WW3 domain constructs showed distinctive differences in peak shift change. Tandem WW3
residues 414Arg and 420Val, in particular, had larger changes in shift (Figure 4D), while three additional
tandem WW3 residues were in intermediate exchange between bound and free states (Table S4).
Further, comparison of the free HSQC amide peaks revealed differences in chemical shift across the
entire domain (Figure 4G) and peaks that were missing in the tandem WW3 due to conformational
exchange. This suggests that the WW3 conformation is influenced by the presence of WW4, sampling
multiple conformations in the absence of Smad7. The increase in affinity for WW3 is in agreement with
observations made of other tandem WW domains which often exhibit cooperation [30]. Unfortunately,
this mechanism could not be explored structurally because of the conformational exchange in the
WW3–4 construct. Instead, we were able to confirm the secondary structure of WW3, predicted from
the backbone chemical shifts by the CSI 3.0 webserver [51]. This showed a three β-strand conformation
typical of other WW domains, albeit with longer loop regions when compared to WW4 (Figure 4D
and Figure S5D). By mapping the titration data to the secondary structure, we found that all amide
resonances belonging to the third WW3 β-strand bound Smad7 in intermediate exchange, both in
tandem orientation and as a single domain. Unlike WW4, WW3 residues belonging to loop 1 were also
involved in ligand coordination. This is a notable feature of other NEDD4 family WW domains with
high Smad7 affinity [32,52].
3. Discussion
We presented here the previously unreported structure of the fourth WW domain of WWP2
and showed that it holds the typical three-stranded antiparallel β-fold found in other WW domains.
The WWP2 WW4 domain binds Smad7 with residues across the threeβ-strands but has an unexpectedly
low affinity. However, we found evidence for post-translational modification of Smad7 in close
proximity to the PPxY motif that enhances WW4 affinity in vitro. Furthermore, we provided
evidence for a novel TGFβ-inducible WWP2C-∆HECT isoform that contains tandem WW3–WW4
domains and a potentially catalytically inactive HECT domain and which has the ability to reduce
TGFβ/Smad-dependent gene expression. Notably, the WW3 and WW4 domains of WWP2 were shown
to cooperate in Smad7 ligand coordination when expressed in tandem, significantly enhancing WW3
affinity and demonstrating the importance of tandem WW domains in substrate recruitment by WWP2
isoforms. This has implications on the study of WW domain binding affinities out of their native
environment, as neighbouring domains have the capacity to dramatically alter binding affinity.
We previously showed that WWP2-C has a binding preference for Smad7 over Smad2/3 in vivo
using co-immunoprecipitation experiments [27]. This appears to enhance Smad7 degradation via
WWP2-C and increases Smad2/3-dependent gene expression. We therefore expected to observe high
WW4/Smad7 affinity in vitro, but our results indicate only a moderate affinity. This affinity is lower
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than those of other NEDD4 WW domains, which have dissociation constants in the low micromolar
range [32,52]—although determined using a different biophysical technique. Since inter-domain
and domain-linker effects were found to be important in WW domain interactions both here and in
other studies [30,38,53–55], we can speculate that a WW4 conformation more favourable to Smad7
binding is stabilised by the HECT domain or the linker region. However, studies on WW domains
with low micromolar dissociation constants noted the involvement of extended recognition pockets
where additional WW domain residues along the first β-strand and within loop 1 bind residues
either side of the PPxY motif. For example, the Smad7 co-structure of the SMURF1 WW2 domain
revealed two key interactions between 289ArgSMURF1/217DSmad7 C-terminal to the PPxY motif and
295ArgSMURF1/205ESmad7 N-terminal to the PPxY motif [32]. Mutational analysis of this domain
found that exchanging 295ArgSMURF1 for glutamic acid reduced Smad7 affinity 12-fold, and indeed,
WWP2 WW4 mirrors this substitution exactly, with the equivalent position occupied by 457Glu. This
might confer some selectivity on WW4 towards substrates with basic residues proximal to their PPxY
motifs. On the other hand, the WWP2 WW3 domain has both of these residues conserved (414Arg and
419Arg). Although the WW3 domain contains a deletion prior to 419Arg that might orient this residue
on the opposite side of the β-fold, we observed substantial chemical shift change for both of these
residues during Smad7 titration and a dissociation constant of comparable affinity, suggesting that the
binding mechanism is similar.
The WW4 residue in the equivalent position of 289ArgSMURF1 is 453Lys. This might be expected
to engage in a similar interaction, but in 15 out of 20 models of the structural ensemble, 453Lys
forms a salt bridge with 451Glu and is most likely unavailable to coordinate Smad7 residues. This is
reinforced by observations in Smad7 titration, which showed relatively minor changes in shift for
453Lys (Figure 2E). This is indicative of small changes in the chemical environment and unlikely to be
due to direct ligand coordination. In four of these models, 451Glu also forms polar contacts with the
second specificity pocket histidine. We propose that these interactions are important in NEDD4 WW
domain ligand coordination, where Glu, at the +1 position relative to the first tryptophan, is 100%
conserved, and either Lys or Arg occupy the equivalent position of 453Lys (+3) (Table S1). In several
solved structures [32,56–61], polar contacts are observed between the +3 basic residue and +1 Glu,
which then form polar contacts with the ε2 NH group of the second specificity pocket His (+15). Similar
to the role of the acid/histidine interaction of the catalytic triad [62], this chain might optimise the
orientation and charge distribution at +15 His, which would otherwise be neutral at physiological
pH [63]. This would encourage His to accept polar groups, such as the polar hydroxyl group of
the ligand tyrosine, whose hydrophobic ring then contacts the conserved second specificity pocket
aliphatic residue at +13, as described before [49]. This neutralises the role of +3 Lys in further ligand
selectivity, whereas inclusion of +3 Arg maintains this interaction but allows for additional selectivity
for acidic or phosphorylated residues C-terminal to the PPxY motif through its guanidino group,
as described before [32]. The presence of Lys and not Arg at this position does not appear to prevent
in vivo ubiquitination of Smad7 by WWP2-C [27], which contains only the WW4 and HECT domains.
The binding mechanism in this instance might allow a low-affinity, low-specificity transient interaction
that is sufficient to induce ubiquitination. As discussed above, SMURFs bind to Smad7 and translocate
to the cell surface, a process that would necessitate high-affinity binding. This reduces TGFβ-induced
transcriptional activity by reducing receptor activation of Smads, whereas WWP2-C increases TGFβ
activity by degrading Smad7 to reduce the negative feedback. A weaker, transient interaction might
suit this function in order to minimise ubiquitination of Smad7 binding partners.
Smad7 S206 was identified as a candidate phosphorylation site using prediction servers. This was
corroborated by evidence in the literature that suggests this residue undergoes phosphorylation
in vivo [47]. S206-phosphorylated Smad7 has an increased affinity for WWP2 WW4. Another Smad7
binding partner, YAP, supresses TGFβ signalling by potentiating Smad7 activity [64]. Observations
from a YAP WW1/Smad7 co-structure suggest that phosphorylation at S206 would disrupt the
binding mechanism [65]. Kinase pathway activity may, therefore, switch Smad7 activity from
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YAP-mediated suppression of TGFβ signalling to WWP2-mediated turnover, similar to that of other
Smads [26,66]. This may explain the increased rate of Smad7 turnover we observed in vivo upon
TGFβ stimulation [27], and such cross-talk would allow for contextualised cellular responses to TGFβ
signalling inputs [33,67,68].
Evidence of a catalytically inactive, tandem WW3–WW4 domain-containing WWP2C-∆HECT
isoform suggests a further layer of regulation involving RNA splicing. Alternative splicing has been
shown to be a key component in metastatic phenotypes [69], and TGFβ-mediated splice variation
drives epithelial–mesenchymal transition [50], a commonly misregulated process in carcinomas. As in
the case of WWP2 isoforms, these splicing programmes can regulate signalling cascades by altering
E3 ligase activity. We observed that this putative isoform reduces activity at the Smad promoter.
We cannot conclusively attribute these observations to the conservation of Smad7 inhibitory activity
at this stage, especially since PPxY is a common motif conserved amongst other Smads and because
WW domains are often promiscuous in their choice of binding partners. However, since our titration
data showed a high WW3/Smad7 binding affinity when in tandem conformation, we propose that
the WWP2C-∆HECT isoform participates in protective binding of Smad7. This would potentiate
TGFβ-suppressive activity by competing with catalytically active E3 ligases for access to the PPxY
motif. In the context of metastatic cell lines, in which we found evidence of expression, prolonged
inhibitory activity of Smad7 would allow the cell to escape cytostasis induced by the TGFβ gene
programme. We found that WW4 holds the same conformation and has the same Smad7 binding
mechanism and affinity both as a tandem domain and as a single domain. This might be a necessity for
a WW domain that has to function in both scenarios in vivo as part of both WWP2-FL and WWP2-C.
Our data suggest that as part of WWP2-FL, WW4 faces competition from its high-affinity neighbour,
effectively reducing its role in ligand recruitment.
Our results put WWP2 at the junction of several regulatory networks involving ubiquitination,
phosphorylation, splice variation and promoter activity. This suits the TGFβ signalling paradigm,
where such diverse regulatory inputs allow contextualised responses that drive numerous physiological
processes. The role that Smad7 PPxY motif phosphorylation and WWP2C-∆HECT play in regulating
these physiological processes and their role in disease states where contextualised TGFβ responses
malfunction, will be interesting to study in the future. The WWP2 WW4 atomic structure elucidated
here can be used as the foundation for further study on the rational design of therapeutics to target this
disease-associated E3 ligase with small-molecule or peptidomimetic inhibitors. Indeed, coincidentally,
we have already produced a modified Smad7 peptide with enhanced affinity in the form of pSmad7,
although not systematic in our approach. The identification of binding-site residues makes an important
contribution in this respect, and the binding hotspot residues 470Thr and 471Thr offer a starting
point for targeted design, although the conservation of these residues across other WW domains
poses a challenge when considering specificity. The role of WW3 and the tandem WW3–WW4 pair
have revealed intriguing detail on the WWP2 structure–function relationship and re-emphasised
the importance of tandem WW domains in substrate recruitment. Substrate-bound co-structures
and mutational analysis will provide further valuable information on the interaction interface and
mechanism of tandem-domain cooperation.
4. Materials and Methods
4.1. Protein and Peptide Expression and Purification
GB1-tagged constructs with an N-terminal hexa-His tag were generated by amplifying DNA
fragments of single or tandem WWP2 WW domains and inserting them into the pSKDuet01 vector
(Addgene plasmid #12172) using BamHI and HindIII restriction sites. SUMO-tagged constructs with
an N-terminal hexa-his tag were generated by amplifying a Smad7 DNA fragment corresponding to
Ser199 to Asp217 and inserting them into a modified pET21d(+) vector (a gift from Dr Robin Maytum,
University of Bedfordshire) using BsaI and BamHI restriction sites. Single-15N isotope-labelled and
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double-15N, 13C isotope-labelled proteins were expressed in E. coli BL21 Star (DE3) (Fisher Scientific)
using isotope-enriched M9 minimal medium supplemented with micronutrients and MEM vitamin
solution (Sigma). Unlabelled proteins were expressed in LB medium using E. coli BL21 Star (DE3)
(Fisher Scientific). Cells were harvested by centrifugation, and lysates were produced using a
French Press at 10,000 psi. Recombinant proteins were purified using nickel-charged HisTrap FF
columns (GE Healthcare) and the ÄKTA-FPLC system (GE Healthcare). ULP-1 (ubiquitin-like-specific
protease-1) was used to cleave peptide His-SUMO tags overnight in Tris buffer. Protein His-tags
were cleaved by thrombin digestion overnight in PBS. Tags were removed by a second round
of nickel-affinity purification. Recombinant proteins were purified further by size-exclusion
chromatography using the HiLoad 16/600 Superdex 75 prep grade column (GE Healthcare). Proteins
were concentrated and prepared for NMR using 20 mM Na2HPO4, pH 6.8, 50 mM NaCl, 200 µM
4,4-dimethyl-4-silapentane-1-sulfonic acid, 10% D2O v/v and NaN3 0.03% buffer. Protein concentrations
were determined using extinction coefficients and absorbance at 280 nm. Synthetic peptides were
purchased from Proteogenix, France.
4.2. NMR Spectroscopy
NMR data were collected at 298 K using either a Bruker Avance III 800 MHz spectrometer
or a Bruker Avance I 500 MHz spectrometer. The spectra used for the backbone and sidechain
assignment were: 1H-15N-HSQC, 1H-13C-HSQC, CBCA(CO)NH, HNCACB, CC(CO)NH, H(CCO)NH,
H(C)CH-TOCSY, (H)CCH-TOCSY, hbCBcgcdceHE, hbCBcgcdHD, 1H-13C-TROSY-HSQC centered in
the aromatic region, and a 1H-1H 2D plane of 13C-NOESY-HSQC with the 13C centered at 120 ppm
(50 ms mixing time). Acquisition parameters can be found in Table S5. Through-space distance
restraints for the structural calculation were determined with 15N-NOESY–HSQC (100 ms mixing time)
and 13C-NOESY–HSQC (100 ms mixing time) spectra. Spectra were processed using the NMRPipe
software suite [70] and analysed using the CCPNmr Analysis software package [71].
4.3. NMR Ligand Titration
Synthetic peptide: 15N-labelled protein was prepared at 0.78 mM, and 100 mM Smad7 or
pSmad7 peptide was titrated in seven increments (1:0, 1:0.1, 1:0.2, 1:0.5, 1:1, 1:2, 1:4) to a ratio
of 1:4. A 1H-15N-HSQC spectrum was taken at each titration point.
Recombinant peptide: Two samples of each 15N-labelled protein were prepared at 0.08 mM, one
of which contained unlabelled Smad ligand at a ratio of 10:1. A titration was performed at 298 K by
replacing aliquots of the non-ligand sample with aliquots of the ligand sample at increasing volumes,
so that ligand concentration increased while protein concentration and sample volume remained the
same. Ten titration increments were performed (1:0, 1:0.1, 1:0.2, 1:0.5, 1:1, 1:1.9, 1:3.6, 1:5.2, 1:6.8, 1:8.4).
A 1H-15N-HSQC spectrum was taken at each titration point.
4.4. Dissociation Constants
Changes in shift of amide peaks were weighted according to gyromagnetic ratio. For single-domain
titrations, the following protein-ligand fast-exchange equation was fit to the saturation curves of each
amide resonance using CcpNmr Analysis [71]. Residues with shift distances larger than or equal to the





(B+ x)2 − 4x
)
a = total protein concentration
b = total ligand concentration
x = b/a
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y = change in observed chemical shift
A = ∆δ∞/2
B = 1+Kd/a
∆δ∞ = difference between start chemical shift and shift at saturation
For each tandem domain binding site, residues with shift distances larger than or equal to the
mean shift distance plus one standard deviation were averaged, and these two means were summed.
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x = ligand concentration
y = change in observed chemical shift
K1 = KD binding site 1
K2 = KD binding site 2
δ1 = difference between binding site 1 start chemical shift and shift at saturation
δ2 = difference between binding site 2 start chemical shift and shift at saturation
[P] = protein concentration
4.5. Structure Determination
Unassigned 13C-NOESY–HSQC and 15N-NOESY–HSQC distance restraints were calculated
with CCPNmr Analysis [71], and ϕ and ψ dihedral restraints were calculated using DANGLE [74].
Both sets of restraints, the 13C-NOESY-HSQC and 15N-NOESY-HSQC spectra, were used to calculate
the 20-model refined protein structure ensemble using ARIA software embedded in the CCPN grid
and the WeNMR ARIA 1.2 HJ webportal [75–78]. The ensemble was validated using PSVS 1.5 [79],
Molprobity [80] and wwPDB [81]. The coordinates were deposited in the Protein Data Bank under
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accession code 6RSS. RMSD values were generated for well-defined regions (construct residues 3–59
for GB1 and 75–101 for WW4), as determined by wwPDB.
4.6. Cytokine Stimulation and Immunoblotting
HEK-293 cells were transfected with mouse or human ESRP homologue expression plasmids as
described previously [82]. Cells were stimulated with 5 ng/mL TGFβ for 1 h, washed in ice-cold PBS,
and lysed in 1% v/v Igepal-630, 50 mM Tris pH 8.0, 150 mM NaCl, 10% v/v glycerol, 5 mM EDTA,
1 mM NaF, 1 mM Na3VO4 and protease inhibitors (1% NP-40 LB), in the ratio 1 tablet (Roche):30 mL
1% NP-40LB. Clarified lysates were boiled in Laemlli buffer with DTT and analysed by western blot
using anti-WWP2 antibody specific for a C-terminal epitope (Santa Cruz Biotechnology).
4.7. Semi-Quantitative RT-PCR
RNA was extracted from TGFβ-stimulated A375, COLO357, SK-MEL28 and VCaP cells at
increasing time intervals using the SV Total RNA Isolation kit (Promega). Reverse transcription
was performed using random primers (Promega) and GoScript reverse transcriptase (Promega).
WWP2-∆HECT specific primers (Forward: 5’-GCTGGGAAGAACAATTACTG-3’ Reverse: 5’-TTCC
TCTGTAACATGCTCCCT-3’) were used in conjunction with the GoScript kit (Promega), and the DNA
products were analysed using 1% agarose-TAE gel.
4.8. Luciferase Reporter Assays
The Smad3 reporter construct (pCAGAC12-luc) was kindly provided by Caroline Hill (CRUK
Laboratories, Francis Crick Institute, UK). For each plasmid transfection, 250 ng pCAGAC12-luc-
and 15 ng pRSV-β-galactosidase (pRSV-βgal)-encoding plasmid were used in conjunction with
Smad-encoding plasmids, as described previously [27]. Values were averaged, luciferase activity
standardised for β-galactosidase activity, and data expressed as relative fold changes in luciferase
activity over basal activity.
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4682/s1, Figure S1A: Backbone amide T1 relaxation constants for residues of the GB1-WW4 construct. GB1:
residues 1–61, Linker: residues 62–66, WW4: residues 67 114; Figure S1B: Backbone amide T2 relaxation constants
for residues of the GB1-WW4 construct. GB1: residues 1–61, Linker: residues 62–66, WW4: residues 67 114;
Figure S1C: Backbone amide 1H-15N NOE relaxation for residues of the GB1-WW4 construct. GB1: residues 1-66,
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depiction of the refined 20-model WW4 domain structural ensemble; Figure S3A: The superimposed WW4/Smad7
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grey; Figure S3B: The superimposed WW4/pSmad7 titration HSQCs. Lower ligand concentrations are in light
blue and higher ligand concentrations are in dark blue; Figure S4A: The nucleotide sequence of the predicted
WWP2-∆HECT promoter within intron 9/10. Putative AP 1, Smad [5] and SOX9 responsive elements highlighted
in purple, cyan and yellow respectively. TATA boxes are highlighted in grey; Figure S4B: Luciferase activity of the
prospective WWP2-∆HECT 2 kb promoter region under different growth factor conditions in HEK293A cells;
Figure S4C: Luciferase activity of different regions of the prospective WWP2-∆HECT promoter in HEK293A cells;
Figure S5A: The superimposed WW3-4/Smad7 titration HSQCs. Lower ligand concentrations are in light orange
and higher ligand concentrations are in dark orange; Figure S5B: The superimposed WW3/Smad7 titration HSQCs.
Lower ligand concentrations are in light green and higher ligand concentrations are in dark green; Figure S5C: The
superimposed WW4/Smad7 titration HSQCs. Lower ligand concentrations are in light purple and higher ligand
concentrations are in dark purple; Figure S5D: The CSI 3.0 webserver [6] output predicting the secondary structure
of WW3 based on backbone chemical shifts; Table S1: Clustal Omega [1] alignment of NEDD4 WW domains. (An
asterisk indicates fully conserved residues. A colon indicates residues with strongly similar properties. A full
stop indicates weakly similar properties.); Table S2: GPS 3.0 phosphorylation prediction [2] at S206 of human
Smad7; Table S3: NetPhos 3.1 phosphorylation prediction [3,4] at S206 of human Smad7; Table S4: Residues in
intermediate exchange in WW3/Smad7 and WW3-4/Smad7 titrations; Table S5: Acquisition parameters for the
GB1-WW4 NMR spectra.
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GB1 B1 domain of streptococcal protein G
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